Alkermes (NASDAQ:ALKS) Issues FY 2025 Earnings Guidance

Alkermes (NASDAQ:ALKS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.030-1.210 for the period, compared to the consensus EPS estimate of 1.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Ratings Changes

Several research analysts recently issued reports on ALKS shares. Stifel Nicolaus upgraded Alkermes from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $25.00 to $36.00 in a research report on Tuesday, November 5th. HC Wainwright restated a “neutral” rating and issued a $37.00 price objective on shares of Alkermes in a research report on Friday, October 25th. Piper Sandler restated an “overweight” rating and issued a $37.00 target price (down from $38.00) on shares of Alkermes in a report on Friday, October 25th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Alkermes in a report on Tuesday. They set a “buy” rating and a $40.00 price target for the company. Finally, JPMorgan Chase & Co. lowered their target price on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $36.33.

Alkermes Trading Up 2.4 %

Shares of ALKS stock traded up $0.77 during mid-day trading on Wednesday, reaching $32.73. The company’s stock had a trading volume of 858,619 shares, compared to its average volume of 1,520,002. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $5.30 billion, a PE ratio of 16.78, a price-to-earnings-growth ratio of 1.83 and a beta of 0.49. The company’s 50 day simple moving average is $30.16 and its 200-day simple moving average is $28.65. Alkermes has a 12-month low of $22.90 and a 12-month high of $33.00.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. On average, research analysts predict that Alkermes will post 2.23 EPS for the current fiscal year.

Insider Activity at Alkermes

In other news, EVP Craig C. Hopkinson sold 9,221 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $31.50, for a total value of $290,461.50. Following the completion of the sale, the executive vice president now directly owns 59,730 shares of the company’s stock, valued at approximately $1,881,495. This represents a 13.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Christian Todd Nichols sold 5,208 shares of Alkermes stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the completion of the transaction, the senior vice president now directly owns 60,703 shares in the company, valued at $1,769,492.45. This represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 179,189 shares of company stock worth $5,723,518. 4.89% of the stock is currently owned by company insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.